Nonabsorbable Proton-Binding Polymer for Hidden Metabolic Acidosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic kidney disease patients with serum bicarbonate levels around 22 mEq/l experience eubicarbonatemic metabolic acidosis, which is masked by the body's homeostatic mechanisms, leading to pathologic consequences such as nephrolithiasis, bone loss, and muscle protein breakdown, despite normal serum bicarbonate levels, and current treatments like oral sodium bicarbonate are not effective due to sodium and potassium excretion issues.
Innovation Solution
Administration of a nonabsorbable proton-binding polymer that absorbs and removes protons and conjugate bases, effectively treating or preventing eubicarbonatemic metabolic acidosis by reducing the overall acid load before it progresses to chronic metabolic acidosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bicarbonate is administered to treat metabolic acidosis, then acid-base balance is corrected, but intracellular acidosis is worsened and potassium levels increase dangerously
Solution Approach 1:
The patent changes the chemical parameter of the buffering agent from bicarbonate (HCO3-) to alternative buffering agents such as lactate, malate, or acetate. These alternatives metabolize to produce bicarbonate in situ, avoiding the direct intracellular acidosis and hyperkalemia caused by exogenous bicarbonate administration, while still achieving acid-base balance correction
Solution Approach 2:
The patent introduces intermediary metabolites (lactate, malate, acetate) that serve as precursors to bicarbonate. These intermediaries are converted endogenously to bicarbonate through metabolic pathways, providing a间接 mechanism for bicarbonate generation that avoids the harmful direct effects of exogenous bicarbonate administration
2Reliability
If traditional buffering agents are used, then acidosis is treated, but the treatment mechanism is insufficiently understood and may cause adverse effects
Solution Approach 1:
The patent employs buffering agents that utilize the body's own metabolic pathways to generate bicarbonate. The administered compounds (lactate, malate, acetate) are processed by endogenous enzymes and metabolic circuits, allowing the body's own systems to perform the bicarbonate generation function rather than requiring external bicarbonate administration
Solution Approach 2:
The patent changes the chemical identity of the buffering agent from bicarbonate itself to metabolizable precursors. This parameter change transforms the treatment mechanism from direct buffering to metabolic conversion, leveraging well-understood metabolic pathways while achieving the desired therapeutic effect with reduced adverse effects
3Measurement precision
If bicarbonate is administered, then blood pH increases, but intracellular pH decreases and cellular function is impaired
Solution Approach 1:
The patent changes the administration approach from direct bicarbonate (which causes rapid blood pH increase and intracellular acidosis) to metabolizable buffering agents that generate bicarbonate gradually through metabolic conversion. This results in more gradual and controlled pH changes that maintain intracellular pH stability while achieving blood pH correction
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymer effectively increases serum bicarbonate levels, normalizes markers of acid-base imbalance, and prevents progression to chronic metabolic acidosis, reducing the risk of complications in chronic kidney disease patients.
Implementation Method 1
Compositions comprising a metabolizable buffering agent, such as lactate, malate, or acetate, which can be metabolized to generate bicarbonate
Data Source
Figure 1A~1B
Figure 1C
Figure 2~3C
AI summary
The present disclosure provides, inter alia, pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. In certain embodiments, the pharmaceutical compositions contain nonabsorbable pharmaceutical composition and may be used, for example, to treat eubicarbonatemic metabolic acidosis.